Brazil’s AMB seeks to block Amil’s telemedicine plans amid legal uncertainty



The Brazilian Medical Association (AMB) this week filed a complaint with the National Regulatory Agency for Private Health Insurance and Plans (ANS) over the rise of unregulated online health consultations offered by private facilities. The complaint was specifically raised in relation to Amil Participacoes SA, Brazil's largest health insurer and hospital operator, which recently began to offer virtual medical consultations.

Amil is reportedly set to provide a 24-hour telemedicine service offering diagnosis and potential drug prescribing for patients with mild complaints, the source citing sicknesses such as coughs and colds, stomach pains, diarrhea, nausea, allergies, headaches, backache, or eye complaints. Doctors will be permitted to prescribe drugs over the service where they feel confident in being able to give a diagnosis. The president of UnitedHealth Group Brazil, which owns Amil, Claudio Lottenberg, underlined that there are no legal issues with this service: “There is already a standardized mechanism for prescription drugs through digital certification" in Brazil. The online consultation service will initially be restricted to the 180,000 beneficiaries on the Amil One private insurance plan, but with plans to expand the scope in the near future.

The AMB stated that it has concerns for patients' health and the legal status of Brazilian physicians providing such services, and called for the ANS to step in and curb such activities immediately.

The legal environment for telemedicine is in something of a grey area at present after a resolution addressing the provision of virtual medical care – Resolution 1643 of 2002 – was published by the Federal Medical Council (CFM) in February this year, but later repealed after regional opposition. The CFM states it will begin receiving public feedback on revisions to that legislation from the end of this month.


Reference:

Related news
Peru’s telemedicine network has provided mammogram studies to 11,274 women so far.
Peru has added 16 healthcare centers to its national telehealth network, which now has 1,101 facilities connected in all regions of the country, and is the largest system of its kind in Latin America.
Isreali telemedicine firm TytoCare was backed with USD 33.5 million in a Series C funding round recently, with the Ping An Global Voyager Fund the lead investor, and participation from Shenzhen Capital Group of China, Japan’s Itochu, and U.S.-based Sanford Health. TytoCare was founded in 2012, and is aimed at providing a disruptive telehealth platform that enables anyone to perform a comprehensive remote examination and consultation with a physician from any location.
Ping An Healthcare and Technology Co., Ltd, (1833.HK) has formed a multi-faceted partnership with Hong Kong-based healthcare services provider UMP Healthcare Holdings Ltd, (722.HK), and Zheng He Health and Medical Resources Ltd. The deal will see UMP provide training to Ping An Good Doctor’s medical team under the UMP’s General Practice Oriented Learning and Development (GOLD) Training Program.
China’s National Health Commission (NHC) issued three separate trial measures setting out management measures for the fields of “online diagnosis and treatment”, “online hospitals”, and “online telemedicine”.
Recent news
The Brazil-based Institute of Technology and Pharmaceuticals (Farmanguinhos), the drug making unit of the Oswaldo Cruz Foundation (Fiocruz), has delivered its pilot batches of hyperprolactinemia (HPRL) treatment cabergoline, the result of a Productive Development Partnership (PDP) with compatriot laboratory Cristália that concluded this year.
Brazil’s National Health Surveillance Agency (ANVISA) this week granted registration approval to Eli Lilly’s biologic drug Emgality (galcanezumab-gnlm), as revealed by GBI analysis.
The new Science and Technology Innovation Board (STAR) hosted by the Shanghai Stock Exchange (SSE) opened for business on July 22.
Belgium-based UCB announced the market approval in China for Cimzia (certolizumab pegol), for the indication of moderate-to-severe rheumatoid arthritis (RA).
  • 1563867876525
  • China
  • Drug
Denmark-based diabetes specialist Novo Nordisk has invested MXN 400 million (USD 21 million) in clinical research in Mexico between 2014 and 2018, involving 1,200 patients in 21 trials.
The Shandong Centralized Drug Procurement platform released a notification in relation to public hospital drug and consumables procurement alliances.
The “4+7” volume-linked drug procurement pilot scheme introduced at the end of 2018 in 11 cities is set to be expanded to all regions of the country, following a meeting between the National Health Security Administration (NHSA) and industry stakeholders held last week.
  • 1563857070043
  • China
Analytics Snapshot


Analytics Snapshot